# SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

> **NCT07646626** · PHASE2 · RECRUITING · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 150 (estimated)

## Conditions studied

- Locally Advanced (Unresectable) or Metastatic Solid Tumors

## Interventions

- **DRUG:** SSGJ-705
- **DRUG:** SSGJ-612
- **DRUG:** SSGJ-705 combined with chemotherapy

## Key facts

- **NCT ID:** NCT07646626
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-17
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-10-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07646626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07646626, "SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07646626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*